Navigation Links
PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
Date:2/1/2012

ates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $2.0 million in the third quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 as filed with the SEC on November 9, 2011, which "Ri
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
2. PAREXEL International to Present at J.P. Morgan Healthcare Conference
3. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
4. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
5. PAREXEL Ranks as a "Best 5 Outsourcing Company for the Pharmaceutical Industry" by IAOP®
6. PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM)
7. PAREXEL International to Present at Wells Fargo Healthcare Conference
8. Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development
9. PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results
10. PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call
11. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Hershey, PA & Rockville, MD (PRWEB) September 17, 2014 ... it won a Small Business Innovation Research (SBIR) grant ... allergy immunotherapy. The award will provide ITI with approximately ... , Tree nuts, a leading cause of food allergy, ... leading cause of anaphylaxis behind peanut allergy. Tree nut ...
(Date:9/17/2014)... 17, 2014 Terracon Corporation has announced ... TerraPure tank . This addition to the company’s ... FDA-compliant linear polyethylene and available in 125 or 250 ... ships in two weeks or less. , The new ... found in Terracon’s existing TerraPure tank line – plus ...
(Date:9/17/2014)... , Sept. 17, 2014 Intarcia Therapeutics, ... data from a study of the cost and predictability ... 50 th Annual Meeting of the European Association ... session today, Christian Frois , Ph.D., of Analysis ... series of planned Intarcia-sponsored, retrospective studies to characterize the ...
(Date:9/17/2014)... Hussey Copper , a leader in copper manufacturing ... Gilmour Academy Ice Arena,s conversion of more than 200 ... surface to help protect against bacteria.  MD-Cu 29 ... greater than 99.9% of MRSA, E-coli and other bacteria ... , Innovative Gilmour Academy prepares children ...
Breaking Biology Technology:Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3
... economy , ,Its a strategy, process and ... reaches across the entire spectrum of local, state, national, ... the life sciences and information technology. We can help ... in tourism, manufacturing, and agriculture to operate in real- ...
... , ,Spring of 99 was a great time to start ... WAVE Program (Weinert Applied Ventures in Entrepreneurship) at the ... and Neil Peters-Michauds Cascade Asset Management . As an ... , ,Our coursework included consulting projects for small technology-based businesses. ...
... Administration (FDA) recently began requiring applicants to pay significant ... medical devices and biologics. Such user fees have long ... required for applications related to devices and biologics. In ... review time, but at what cost? User fees impose ...
Cached Biology Technology:Real-Time Economy: Part 2 2Living in the Unreal World: A Survival Guide for Entrepreneurs 2Living in the Unreal World: A Survival Guide for Entrepreneurs 3Living in the Unreal World: A Survival Guide for Entrepreneurs 4Fast Track: FDA User Fees: Do Faster Review Times Justify the Financial Burden? 2
(Date:9/17/2014)... complex social behavior by studying nonhuman mammals and primates, ... With their unusually large brains relative to their body ... social environment---not merely in a large population of cooperating ... dynamic setting of alliances and competitors. The same is ... and social carnivores, like hyenas and lions. , A ...
(Date:9/17/2014)... MSSA could be curbed by coating hospital surfaces ... of shark skin, according to research published in ... Infection Control . , The study modelled how ... disease bacteria through touching, sneezes or spillages. The ... formulated to resemble shark skin. The study showed ...
(Date:9/16/2014)... at the Columbia Center for Children,s Environmental Health at ... to demonstrate an association between childhood asthma and prenatal ... of household products. Results appear online in the journal ... to mothers exposed during pregnancy to higher levels of ... had a 72 percent and 78 percent increase in ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Sharks' skin has teeth in the fight against hospital superbugs 2Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3
... neuroscientists at the University of Wisconsin-Milwaukee (UWM) are working ... model the company has developed for researching diseases like ... are genetically altered rats, originally created by researchers at ... to clone genes related to human diseases. Called consomic ...
... of Mechanical and Aerospace Engineering Fred Dryer has a ... jet travel. With potentially major benefits for ... Dryer is advancing the fundamental knowledge of jet fuels ... to make alternative jet fuel sources feasible, they need ...
... light-emitting diodes, is intensifying the properties of LEDs by ... constantly think of tiny particles with a negative ... movement of these electrons that electric current flows and ... Steckl is one of the world,s leading experts in ...
Cached Biology News:A new kind of rat model 2Green skies: Engineer's work may reduce jet travel's role in global warming 2Green skies: Engineer's work may reduce jet travel's role in global warming 3Green skies: Engineer's work may reduce jet travel's role in global warming 4Salmon garnish points the way to green electronics 2Salmon garnish points the way to green electronics 3